Stock comparison
Haemonetics
SI-BONE
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
SIBN
SI-BONE
Market cap
$651.05M
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SIBN | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 37D | HAE |
| Benjamin Graham | 85A | 56D | HAE |
| Philip Fisher | 60C | 55C | HAE |
| Peter Lynch | 54C | 40D | HAE |
| Joel Greenblatt | 31F | 2F | HAE |
| Charlie Munger | 54D | 38D | HAE |
| Terry Smith | 55D | 37D | HAE |
Side-by-side metrics
| Metric | HAE | SIBN |
|---|---|---|
| Market cap | $2.98B | $651.05M |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | - |
| ROIC (TTM) | 8.37% | -8.99% |
| Gross margin | 55.74% | 79.59% |
| Net margin | 7.29% | -8.1% |
| Revenue CAGR 5y | 7.65% | 22.18% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- ROIC (TTM)8.37%vs -8.99%+193%
- Net margin7.29%vs -8.1%+190%
- Market cap$2.98Bvs $651.05M+78%
SIBN leads on
- P/E (TTM)-vs 24.8x+167%
- EV/EBIT-vs 14.1x+152%
- Debt / Equity0.0xvs 1.5x+97%
- Revenue CAGR 5y22.18%vs 7.65%+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.